



Media Contact:
Melissa Neill
Java Culture Agency
(651) 295-6761

melissa@javacultureagency.com

FOR IMMEDIATE RELEASE

Long Grove Pharmaceuticals Launches Chemotherapy Medication in Partnership with Sunny Pharmtech

Cyclophosphamide for Injection, USP expands company's growing portfolio of generics

CHICAGO— Dec. 12, 2023 — Long Grove Pharmaceuticals, LLC, a manufacturer of differentiated pharmaceuticals, is expanding its product offerings through a strategic in-licensing of Cyclophosphamide for Injection, USP from Sunny Pharmtech, Inc. Cyclophosphamide for Injection, USP will be manufactured by Sunny Pharmtech, Inc. in Taiwan. The product is an AP-rated generic product and Trade Agreement Act (TAA) compliant.

Cyclophosphamide for Injection, USP is an antineoplastic chemotherapy medication that slows the growth of cancer cells. It is used to treat multiple malignant diseases, including blood cancers and solid tumors. Sunny Pharmtech, Inc. received Food and Drug Administration (FDA) approval for the drug through an Abbreviated New Drug Application (ANDA) in October 2023. It is currently available in 500 milligram, 1 gram and 2 gram dry powder vials.

“Our team at Long Grove Pharmaceuticals has a long history of collaboration with Sunny Pharmtech, Inc.,” said Peter Karas, Chief Commercial Officer at Long Grove Pharmaceuticals. “This current opportunity to jointly offer cyclophosphamide continues our commitment to improving customer choice by increasing access to generics.”

“Our partnership with Long Grove Pharmaceuticals helps ensure we can successfully bring cyclophosphamide to market in the U.S.,” said Yon-Lian Wu, Ph.D., Founder, Chairman and Chief Executive Officer at Sunny Pharmtech, Inc. “We’re excited about the launch of cyclophosphamide, but also by the continued opportunity to collaborate on pharmaceutical products that save and improve lives.”

For more information about Long Grove Pharmaceuticals and Cyclophosphamide for Injection, USP, visit www.longgrovepharma.com.

###

About Long Grove Pharmaceuticals

Long Grove Pharmaceuticals was established in 2019 by Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The company is part of Capstone Development Services, which has been developing products in partnership with the world's premier pharmaceutical and medical device organizations since 2013. Combining

decades of collective leadership experience with a portfolio of specialized, complex generic drug formulations, Long Grove Pharmaceuticals is poised to innovate across the generic injectable and topical markets.

About Sunny Pharmtech, Inc.

Sunny Pharmtech was established in 2014 and received its first FDA ANDA approval in 2017. Based in Taiwan, a TAA country, the company produces non-cytotoxic and cytotoxic active pharmaceutical ingredients, as well as cytotoxic and high-potency oral solid dosage, softgel and injectable drug products. Sunny strives to become a research and development center for high-value products providing process development, scale-up manufacturing and ANDA submission for competing in global markets through worldwide partnership.